Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrasentan in Coronary Endothelial Dysfunction
NCT00271492Phase 3Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2001
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in endothelial dysfunction comparing Atrasentan with Placebo (2 arms). Primary endpoint: Effects of Atrasentan on the heart (Coronary Endothelial Function) at 6 months. Started Jul 2001; status: completed.
02
Drugs
atrasentan
03
Conditions
endothelial dysfunction
Beyond the preview
Go deeper on NCT00271492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271492.